The 29th annual International Cannabinoid Research Society (ICRS) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine.
Just over 500 participants from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data.
Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high-CBD, low-THC sublingual tincture in patients who experience moderate anxiety. None of the participants had been using any cannabinoid-based products prior to this study.
Preliminary data “suggests significant improvement following four weeks of treatment when compared to baseline,” Gruber noted. “Specifically, findings suggest that the use of a custom-formulated, whole plant-derived high CBD sublingual tincture results in
... read more at: https://www.projectcbd.org/cbd-science-update